MEASURE Evaluation PRH Working Paper Series
Copenhagen, Denmark, 7–8 March 2017. Meeting report
A catalyst for transformation in the United Nations to deliver health results for women, children and adolescents in support of the Sustainable Development Goals
The Ministry of Health and Family Welfare is committed to ensuring the effective implementation of this strategy, which will contribute to the overall wellbeing and health of all adolescent boys and girls of Bangladesh
In 2017, 3.6 million of the estimated 10 million people with TB worldwide were “missed” by national TB programmes (NTPs). Two thirds of them are thought to access TB treatment of questionable quality from public and private providers who are not engaged by the NTP. The quality of care provided i...n these settings is often not known or substandard. Closing these gaps and ensuring patient-centred care imply that quality-assured and affordable TB services must be made available wherever people choose to seek care.
more
The case for evidence- based communication of science
WHO’s total revenue in 2020 was US$ 4299 million and total expenses were US$ 3561 million, resulting in a surplus of US$ 824 million, which includes finance revenue (e.g. interest and investment income) of US$ 86 million, representing increases of 38% and 15% in revenue and expenses respectively. ...10. The financial statements report all the Organization’s revenue and expenses. The Organization’s operations are managed under three fund groups: (1) the General Fund, which supports the programme budget, (2) Member States – other, and (3) the Fiduciary Fund (Note 2.18 gives particulars of each of the funds). This segregation of resources facilitates clearer reporting of WHO’s revenues and expenses.
more
BMC Infectious Diseases (2024) 24:1102
Communities living along the shoreline and on the islands of Lake Victoria in northwestern Tanzania
remain endemic for schistosomiasis and suffer from the life-threatening morbidities associated with the disease.
SRHR, HIV AND AIDS Governance Manual
Document No. : FDA/SMC/SMD/GL-RAR/2013/01